Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

NCT07027748 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Neuroblastoma
Neuroblastoma Recurrent
Relapsed Neuroblastoma
Refractory Neuroblastoma

Interventions

DRUG: Naxitamab
DRUG: Irinotecan
DRUG: Temozolomide
DRUG: Sargramostim granulocyte-macrophage colony stimulating factor

Sponsor

Steven DuBois, MD

Collaborators

[object Object]